
Quarterly report 2026-Q3
added 05-06-2026
Accuray Incorporated Revenue 2011-2026 | ARAY
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Accuray Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 459 M | 447 M | 448 M | 430 M | 396 M | 383 M | 419 M | 405 M | 383 M | 399 M | 380 M | 369 M | 316 M | 409 M | 222 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 459 M | 222 M | 391 M |
Quarterly Revenue Accuray Incorporated
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105 M | 102 M | 93.9 M | 102 M | 93.9 M | - | 113 M | 116 M | 102 M | - | 101 M | 107 M | 104 M | - | 118 M | 115 M | 96.5 M | 211 M | 96.2 M | 116 M | 107 M | 224 M | 103 M | 97.5 M | 85.3 M | 97.5 M | 85.3 M | 98.8 M | 89.6 M | 98.8 M | 89.6 M | 102 M | 95.8 M | 114 M | 99.8 M | 100 M | 91 M | 191 M | 97.3 M | 87.5 M | 86.5 M | 87.5 M | 86.5 M | 109 M | 89.6 M | 109 M | 89.6 M | 98.2 M | 82.4 M | 98.2 M | 82.4 M | 93.6 M | 76.6 M | 93.6 M | 76.6 M | 77.8 M | 82.7 M | 77.8 M | 82.7 M | 106 M | 100 M | 106 M | 100 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 224 M | 76.6 M | 102 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
366 M | - | - | $ 3.31 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 11.2 | 0.27 % | $ 317 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 8.24 | 0.24 % | $ 1.24 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
EDAP TMS S.A.
EDAP
|
64.1 M | $ 4.25 | -1.62 % | $ 159 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.88 | 1.38 % | $ 70.3 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Helius Medical Technologies
HSDT
|
6.02 M | $ 2.31 | 6.94 % | $ 50.9 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.47 | -0.57 % | $ 29.2 M | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.79 | 4.12 % | $ 560 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 18.5 | 1.48 % | $ 434 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 73.71 | 1.08 % | $ 4.02 B | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 11.23 | 3.5 % | $ 402 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.0 | -4.76 % | $ 16.9 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.54 | 14.93 % | $ 62.7 M | ||
|
Electromed
ELMD
|
64 M | $ 37.74 | -1.64 % | $ 319 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.91 | 4.17 % | $ 38.1 M | ||
|
Butterfly Network
BFLY
|
97.6 M | $ 4.39 | 6.94 % | $ 1.08 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 12.15 | 0.5 % | $ 481 M | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.21 | 0.45 % | $ 6.13 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Profound Medical Corp.
PROF
|
16.1 M | $ 6.92 | 2.82 % | $ 209 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 84.03 | 5.13 % | $ 11.4 B | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 156.59 | 1.28 % | $ 11 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 37.01 | 2.29 % | $ 1.15 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 44.14 | 3.79 % | $ 1.3 B | ||
|
TransMedics Group
TMDX
|
605 M | $ 68.0 | 2.83 % | $ 2.31 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 91.49 | 1.16 % | $ 3.18 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 82.97 | 0.99 % | $ 48.5 B |